BETHESDA, Md., March 12, 2018 (GLOBE NEWSWIRE) -- India Globalization Capital, Inc. (NYSE American:IGC) today announces that Carrolee Barlow, MD, PhD has been appointed to the Company as an Advisor to help develop solutions and treatments for Parkinson’s disease utilizing cannabis related formulations. Dr. Barlow is a renowned expert in neuroscience & neurodegeneration and is currently the CEO of the Parkinson’s Institute and Clinical Center.
Dr. Barlow’s illustrious career has focused on clinical care, laboratory and clinical research, academia and industry. She is the founder and former Chief Scientific Officer and Chief Medical Officer of BrainCells, Inc. in San Diego, California, a biotechnology company focused on the discovery and development of small molecules that stimulate adult hippocampal neurogenesis for the treatment of neurological and psychiatric disease using human neural stem cell technology. Prior to BrainCells, Dr. Barlow was a professor at Salk Institute for Biological Studies, running a lab that used animal models to study neuro-diseases and eventually helping to establish the field of neurogenomics. After that she supervised neuroscience biology, global exploratory, licensing and full phase efforts as the Director of Molecular Neuroscience and the Therapeutic Area Head for Stroke and Neurodegeneration at Merck Research Laboratories. Moreover, she serves as an advisory board member for several biotechnology companies and disease foundations.
Dr. Barlow received her MD from the University of Utah and did her residency in Internal Medicine at The New York Hospital, Cornell Medical Center. She went on to obtain a PhD in molecular and developmental biology at the Karolinska Medical Nobel Institute in Stockholm, Sweden. Shortly thereafter, she joined the National Institutes of Health and completed medical sub-specialty training in the field of endocrinology and a postdoctoral fellowship in neurogenetics at the National Human Genome Research Institute.
Dr. Barlow’s goal is to find solutions and treatments for Parkinson’s disease in the same way she has done with other diseases. Working with the FDA and others, she is finding ways to transform clinical studies for neurodegenerative diseases by evaluating the science and designing studies in a way that turns research into new treatments.
“We believe that cannabis-based compounds can become part of the solution to treat the symptoms of challenging and progressive medical conditions such as Parkinson’s disease and movement disorders. Dr. Barlow is highly respected in the field and we look forward to working together to bring cannabis-based options to those afflicted by this difficult diagnosis,” stated Ram Mukunda, CEO of IGC.
IGC has two lines of business, a legacy infrastructure and commodity trading business and a cannabis pharmaceutical business that has developed a lead product for treating Alzheimer’s patients. The Company recently announced that it is working on using blockchain to address issues specific to the cannabis industry including transactional difficulties, product labeling, product identification assurance (PIA), and product origin assurance (POA). The Company is based in Maryland, USA.
Please see forward looking statements as discussed in detail in IGC's Form 10K for fiscal year ended March 31, 2017, and in other reports filed with the U.S. Securities and Exchange Commission.